Mathematical Model for Finding Relation Between Asthma And The HPA Axis By Using MDE

S. Lakshmi * and M. Senbagavalli **

* Principal, Government of Arts and Science College, Peravurani-614804, Thanjavur, TamilNadu.
** Research Scholar, UG&PG Research Department of Mathematics, Kunthavai Naacchiyaar Govt. Arts College for Women (Autonomous), Thanjavur, TamilNadu.

Abstract: - The objectives of this paper are to review the relation between Asthma and the HPA axis suppression and its clinical significance in adults and children and to describe methods for diagnosing HPA axis suppression and to explain the implication on selection of treatment for asthma and allergic diseases. Prolonged periods of stress can cause cortisol levels remain elevated, so that some aspects of immune system function continue to be suppressed. This makes the person more susceptible to infections and illness. At the same time, other aspects of the immune system may become unbalanced, which can increase the risk of developing an autoimmune disease, in which the immune system attacks the body’s own cells. Cortisol’s connections to other body systems mean that it can influence allergies. Since hormones play such an important role in regulating the incidence and severity of allergies, it’s not surprising that they also play a role in allergy treatment. Synthetic hormones are used to treat many types of allergies. The Mathematical result for the above applications include the identification of classes of distributions based on mean residual life inequality constraints.

I. INTRODUCTION

1.1. MATHEMATICAL MODEL

Minimum cross-entropy principle is a generalization of the Maximum Entropy (ME) principle for the development of models close to any given distribution instead of the uniform distribution [12]. A Maximum Dynamic Entropy (MDE) procedure for developing lifetime models has been proposed. This may be viewed as an extension of the ME principle in the case that the information is given in terms of hazard rate growth inequality constraints [2,9].

Consider a set of distribution \( \Omega_e = \{ \xi \} \), where \( F \) has PDF \( f \) and is absolutely continuous with respect to a reference distribution \( G \) that has PDF \( g \). The MDDI model in \( \Omega_e \) relative to \( G \) is \( F^* \), with PDF \( f^* \) such that

\[
K ( f^* ; g ; t ) = \int_\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx
\]

for all t \( \geq 0 \).

The following theorem gives the properties of the MDDI distributions in classes of distributions with mean residual life in equality constraints.

Throrem 1.1:

Let \( \Omega_e = \{ \xi : \mu F(t) \leq q(t) \} \) be a compact set of distributions, where \( F \) is absolutely continuous with respect to a reference distribution \( G \). Let \( F^* \in \Omega_e \) be such that \( \mu F(t) = q(t) \). If \( \log ( f^*(x) / g(x) ) \) is decreasing and concave then \( F^* \) is the MDDI distribution relative to \( G \). The same result holds, with \( \Omega_e = \{ \xi : \mu F(t) \geq q(t) \} \), if \( \log ( f^*(x) / g(x) ) \) is increasing and convex.

Proof:

We will prove the case in which \( \mu F(t) \leq q(t) \). First, note that

\[
K ( f ; g ; t ) = \int_t^\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx
\]

\[= \int_t^\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx + \int_t^\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx \]

\[\geq \int_t^\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx, \]

where the inequality is due to the fact that the second integral in (1) equals \( K ( f ; f^* ; t ) \geq t \).

This gives

\[
K ( f ; g ; t ) - K ( f^* ; g ; t ) \geq \int_t^\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx - \int_t^\xi f^* ( x ; t ) \log \frac{f^* ( x ; t )}{g ( x ; t )} dx
\]

\[= \int_t^\xi f ( x ; t ) \log \frac{f ( x ; t )}{g ( x ; t )} dx - \int_t^\xi f^* ( x ; t ) \log \frac{f^* ( x ; t )}{g ( x ; t )} dx \]

\[\geq 0.\]
Since log (f\*(x) / g (x) ) is decreasing and concave and μ F(t) ≤ q (t) = μ F\*(t), the last inequality follows from theorem [11]. The Proof for μ F(t) ≥ q (t) is similar.

When G has a uniform PDF over [x : 0 < x < b], the residual life PDF g (x ; t) is also uniform over [x : t < x < b] and the MDDI model reduces to the MDE model. The MDE model in a set of distribution Ωp = {F} is the distribution with PDF f\*(x) such that H( f ; t) ≤ H ( f\* ; t) for all t ≥ 0.

**Corollary 1:**

Let Ωp = { F : μ F(t) ≤ q (t) } be a compact set of absolutely continuous distributions. Let F\* ∈ Ωp be such that μ F\*(t) = q (t). If log f\*(x) is increasing and log convex then F\* is the MDE distribution. The same results holds with

Ωp = { F : μ F(t) ≥ q (t) },

If f\*(x) is decreasing and log-concave.

Applications of the above results include the identification of classes of distributions based on mean residual life inequality constraints, where the well-known models are MDE, and the development of MDE models for classes of distributions whose mean residual life functions are bounded by a given function q (t) [3,5]. Any continuous function q (t) with the following properties is the mean residual life function of a distribution function F:

- 0 ≤ q (t) < ∞ ;
- q (0) > 0 ;
- q (t) + 1 > 0;
- if q (t0) = 0 for some t0 then q (t) = 0 for all t ≥ t0;
- if q (t) > 0 for all t > 0 then \( \int_{0}^{\infty} \frac{1}{q (t)} \, dt = \infty \).

For any function satisfying (i) − (iv), we can obtain a unique distribution given by the dynamic extensions of the MDI and ME principles in terms of the residual moments. The mean residual life function is defined by

μ F(t) = E[X − t | X > t] = \( \int_{0}^{\frac{1}{\mu F (0)}} \frac{1}{F (x)} \, dx \) if \( F (t) > 0 \),

\( 0 \) if \( F (t) = 0 \).

**Corollary 2:**

Let q (t) = μ F(t) for all t. It is clear that q (t) satisfies (i) − (iv). Then (1.2) gives the exponential distribution with PDF f (x) = (1/μ) e^{-x/μ}. The exponential distribution PDF is decreasing and concave. By Corollary 1, this is the MDE model in the class of distributions with mean residual life μ F(t) ≤ μ.

The MDE model relative to the exponential distribution, with mean residual inequality constraints for generalized normal combination

\[ f (x) = \frac{\sigma^{2}/2\sigma}{\beta} \left[ \frac{(x + \beta)^{2}}{\alpha} - 1 \right] e^{-\gamma/2}(x + \beta)^{2} \] with 0 < α < β²

μ F(t) ≤ \( \frac{n}{t + \beta} \) β² > 3α, μ F(t) ≤ \( \frac{n}{t + \beta} \) β² ≥ 3α,

\[ \lambda = \frac{\beta (q^{2} - 3\alpha)}{\alpha (q^{2} - \alpha)} \]

**APPLICATIONS**

2.1 Asthma and the HPA axis
The objectives of this paper are to review HPA axis suppression and its clinical significance in adults and children and to describe methods for diagnosing HPA axis suppression and to explain the implication on selection of treatment for asthma and allergic diseases [1,5]. When giving Exogenous Prednisone or Dexamethasone for three weeks

When CRH, ACTH and Cortisol are decreased and decreased response to stimulation with Cosyntropin.

Treatment of Asthma and the HPA axis is related to the implications of HPA suppression which leads to subnormal secretion of Cortisol, suppression of growth, Osteopenia, severe Myalgia, Weakness, Fatigue, inability to respond to stress (surgery, shock, sepsis etc) and Cushingoid obesity/syndrome [8,10]. But no clinical adverse effects and asymptomatic. Asthmatic HPA axis suppression and its clinical significance to describe methods for diagnosing HPA axis suppression and to explain the implication on selection of treatment for asthma and allergic diseases [13].
Mean(SE) plasma concentrations of (A) fluticasone propionate and (B) Budesonide in health subjects and subjects with moderately severe Asthma

2.2 Relevant to Asthma
Adrenal Insufficiency => (i) Primary (Addisons Disease, Autoimmune, TB) (ii) Secondary (Corticosteroids)

Primary study outcomes- is there blunted or reduced basal HPA axis – serum cortisol, dynamic HPA axis-response to low dose cosyntrupin and clinically meaningful suppression is when cosyntrupin response is impaired in patients with asthma [4,15].

Diagnosis of secondary adrenal insufficiency from corticosteroids to the background of oral or high orally inhaled corticosteroids block release of CRH and ACTH, low cortisol, impaired response to ACTH and impaired or no response to CRH [14].

III. MATHEMATICAL RESULT

IV. CONCLUSION

The Mathematical result for the above applications include the identification of classes of distributions based on mean residual life inequality constraints, where the well known model are Maximum dynamic entropy and its development of classes of distributions whose mean residual life functions are obtained and are bounded. MDE model relative with mean residual inequality constraints for the density functions are obtained and well defined in the above Fig.3.1. When the rate of the parameters of \( \alpha \) and \( \beta \) of the corresponding medical curves in the cases of Asthmatic and Healthy subjects are increased the corresponding probability density functions are also increased.

Combinations of intranasal and orally inhaled corticosteroids in recommended doses would not cause HPA axis abnormalities. First pass effect (liver metabolism) minimizes oral bioavailability (Fluticasone, Mometasone, Budesonide). Systemic absorption of inhaled Corticosteroid dry power inhalers in patients matters less in patients with asthma compared to normal subjects, drug specific. There is no additive HPA suppression, when there is nasal and Bronchial administration.

V. ACKNOWLEDGEMENT

This work have been carried out by the authors under the MRP fund of UGC XI Plan from Government of India, New Delhi.

REFERENCES